Omeros’ efforts to get its transplant drug to market have already suffered one FDA rejection. | Omeros’ efforts to get its ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Evotec’s sweeping reorganization has claimed roughly 600 jobs since last March, 200 more than were originally planned under a ...

Shortly after welcoming a new CEO, robot developer Vicarious Surgical reported that it will be delaying the clinical trials ...

Prelude Therapeutics’ lead asset won’t be making it to the second act. | Prelude Therapeutics’ lead asset won’t be making it ...

Blood oxygen tracking is returning to the Apple Watch after an 18-month hiatus, through a software update effective today.  | ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find the cash to take its ...

A patient has died from kidney injury in a trial of ’ lead antibody-drug conjugate, although the biotech has been advised to ...

Vedanta Biosciences’ dreams of using live bacteria to treat inflammatory bowel disease (IBD) have been dashed. | Vedanta ...